NCT06564870 (DURVABREIZH) is a clinical trial in Bronchial Cancer, sponsored by University Hospital, Brest.

Who is sponsoring NCT06564870?

NCT06564870 is sponsored by University Hospital, Brest.

What condition does NCT06564870 study?

NCT06564870 studies Bronchial Cancer.

Is NCT06564870 still recruiting?

NCT06564870 is currently active, enrolled. Last updated 21 August 2024.

Last reviewed 2024-08-21 · How we verify

NCT06564870: DURVABREIZH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer

Active, enrolled Last updated 21 August 2024

What this trial tests

trial in Bronchial Cancer in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 June 2021

Primary endpoint
30 June 2023

30 December 2024

Quick facts

Lead sponsor	University Hospital, Brest
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 June 2021
Primary completion	30 June 2023
Estimated completion	30 December 2024
Sites	1 location across France

Conditions studied

Bronchial Cancer — all drugs for Bronchial Cancer →

Sponsor

University Hospital, Brest

Who can join

Adults 18 to 99, any sex, with Bronchial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the real-life efficacy of durvalumab treatment in consolidation after radio-chemotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Brest trials

Trials by the same sponsor.

NCT07526688 — Aerobic Physical Activity and Orofacial Myofascial Pain · NA · not yet recruiting
NCT07487155 — Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Dis · NA · not yet recruiting
NCT07417605 — Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiatio · not yet recruiting
NCT07302074 — Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations a · NA · recruiting
NCT06441773 — Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated W · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06564870 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Brest
Last refreshed: 21 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06564870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing